Posts Tagged ‘obesity treatment’

Progress Reported in MASH with Survodutide

February 27, 2024 — Yet another GLP-1 agonist in development for obesity – survodutide – showed promising results yesterday from a phase 2 clinical trial in MASH. In case you missed the notice, MASH is the new acronym for what we used to label as NASH. We also note that MASLD has replaced NAFLD in the nomenclature alphabet soup […]

CDC Leaders Call for Both Obesity Prevention and Care

February 21, 2024 — Should this be surprising? Probably not. It had to come to this. But this is a pleasant bend in a long arc toward a more realistic approach for obesity at the U.S. Centers for Disease Control and Prevention. Three leaders at CDC write in Health Affairs Forefront that we need both prevention and care to […]

Possible Benefits for Brain Function from Obesity Treatment

February 20, 2024 — The potential for benefits to brain function with effective obesity treatment is becoming difficult to miss. In particular, a new observational study of brain function in a cohort of patients receiving metabolic surgery for treatment of obesity is drawing much attention right now in JAMA Network Open. It suggests the possibility of a lasting benefit […]

Want to Control Hypertension? Treating Obesity Helps

February 8, 2024 — This is not exactly startling news. But two new studies this week do offer a very clear confirmation of one of the important benefits that comes from treating obesity – unmistakably better control of hypertension. One reason this is important is the substantial amount of disinformation that circulates to suggest obesity is not a real […]

More News Points to Explosive Growth for GLP-1 Medicines

February 7, 2024 — Let’s be clear from the start. Hype about “weight loss” drugs is exquisitely unhelpful. This is because weight loss is only an acute effect of new medicines that act on GLP-1 receptors and related pathways that influence obesity. The real need for these medicines is to control a whole range of chronic health problems that […]

Rethinking the Dosing of Obesity Medicines with AMG 133

February 6, 2024 — We learned recently that questions about the need for ongoing dosing with obesity medicines raise discomforting thoughts. After all, obesity is a chronic disease, so we can’t dispute the need for continued daily or weekly doses with obesity medicines. Or can we? Amgen seems to think we can. Monthly Dosing? Induction and Maintenance? With a […]

Make Believe About Obesity Blended with a Social Agenda

February 3, 2024 — We confess to a significant amount of fatigue with a social agenda related to size and weight getting overlaid on the medical concern of obesity. The bickering of people who want to make believe that obesity is a purely social issue can be too much to bear. This has been one of those weeks. Moral […]

The Essence of Autonomy in an Obesity Bill of Rights

February 1, 2024 — Yesterday, the National Consumers League and the National Council on Aging introduced the Bill of Rights for People with Obesity. At the heart of eight simple points in this document is a demand of respect for the dignity and autonomy of people living with obesity. 1. The Right to Accurate, Clear, Trusted, and Accessible Information […]

Weight Regain in the Real World vs a Placebo-Controlled Trial

January 30, 2024 — It created quite a stir last week when Epic Research published an analysis suggesting that weight regain in the real world does not look the same as a placebo-controlled trial. After all, regain is quite an important subject. Obesity is clearly a chronic disease, requiring chronic care. But lots of people try to avoid this […]

A Parody in Scientific American Too Early for April Fools

January 29, 2024 — Scientific American published an entertaining parody last week. It was a bit extreme and too early for April Fools’ Day, but entertaining nonetheless. This essay wove together a litany of absurd rationalizations we hear all the time to tell the tale of a medical breakthrough in obesity taking us down a road to ruin. Hilarious […]